858362-83-1 Usage
General Description
4-(aminomethyl)picolinonitrile, also known as Ampicillin, is a chemical compound used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. It is a derivative of pyridine and contains an amino group and a nitrile group, making it a versatile building block for the production of a wide range of pharmaceuticals. Ampicillin is an important ingredient in the synthesis of drugs used to treat bacterial infections, as it has antimicrobial properties and is effective against a variety of bacteria. Its structure and reactivity make it a valuable tool for medicinal chemists in the development of new pharmaceuticals, and it is widely used in the production of antibiotics and other medications.
Check Digit Verification of cas no
The CAS Registry Mumber 858362-83-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,8,3,6 and 2 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 858362-83:
(8*8)+(7*5)+(6*8)+(5*3)+(4*6)+(3*2)+(2*8)+(1*3)=211
211 % 10 = 1
So 858362-83-1 is a valid CAS Registry Number.
InChI:InChI=1/C7H7N3/c8-4-6-1-2-10-7(3-6)5-9/h1-3H,4,8H2
858362-83-1Relevant articles and documents
Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: A potent and orally bioavailable NCX inhibitor
Kuramochi, Takahiro,Kakefuda, Akio,Yamada, Hiroyoshi,Tsukamoto, Issei,Taguchi, Taku,Sakamoto, Shuichi
, p. 4022 - 4036 (2007/10/03)
Ca2+ overload in myocardial cells is responsible for arrhythmia. Sodium-calcium exchanger (NCX) inhibitors are more effective than sodium-hydrogen exchanger (NHE) inhibitors with regard to modulation of Ca 2+ overload, because NCX inhibitors can directly inhibit the influx of Ca2+ into cells. NCX is an attractive target for the treatment of heart failure and ischemia-reperfusion. We have designed and synthesized a series of N-(2-aminopyridin-4-ylmethyl)nicotinamide derivatives, based on compound 5. We have discovered a novel NCX inhibitor (23h) with an IC 50 value of 0.12 μM against reverse NCX. The inhibitory activities of our NCX inhibitors against cytochrome P450 were also evaluated. The effects on heart failure and the pharmacokinetic profile of compound 23h are discussed.
